cd-3254 and Skin-Neoplasms

cd-3254 has been researched along with Skin-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for cd-3254 and Skin-Neoplasms

Article	Year
An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene. International journal of molecular sciences, 2022, Dec-19, Volume: 23, Issue:24 Bexarotene is an FDA-approved drug for the treatment of cutaneous T-cell lymphoma (CTCL); however, its use provokes or disrupts other retinoid-X-receptor (RXR)-dependent nuclear receptor pathways and thereby incites side effects including hypothyroidism and raised triglycerides. Two novel bexarotene analogs, as well as three unique CD3254 analogs and thirteen novel NEt-TMN analogs, were synthesized and characterized for their ability to induce RXR agonism in comparison to bexarotene ( Topics: Bexarotene; Humans; Leukemia; Liver X Receptors; Lymphoma, T-Cell, Cutaneous; Retinoid X Receptors; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Triglycerides	2022

Article

Year

An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.

International journal of molecular sciences, 2022, Dec-19, Volume: 23, Issue:24

Bexarotene is an FDA-approved drug for the treatment of cutaneous T-cell lymphoma (CTCL); however, its use provokes or disrupts other retinoid-X-receptor (RXR)-dependent nuclear receptor pathways and thereby incites side effects including hypothyroidism and raised triglycerides. Two novel bexarotene analogs, as well as three unique CD3254 analogs and thirteen novel NEt-TMN analogs, were synthesized and characterized for their ability to induce RXR agonism in comparison to bexarotene (

Topics: Bexarotene; Humans; Leukemia; Liver X Receptors; Lymphoma, T-Cell, Cutaneous; Retinoid X Receptors; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Triglycerides

2022